重点通报！光伏板块集体狂欢！SNEC展重磅消息引燃市场热情

光伏板块集体狂欢！SNEC展重磅消息引燃市场热情

上海 – 6月13日，SNEC第十七届（2024）国际太阳能光伏与智慧能源（上海）大会暨展览会盛大开幕，为期三天的行业盛会吸引了全球光伏产业链上下游企业和嘉宾齐聚一堂，共同探讨光伏产业发展新趋势、新机遇。

受此利好消息刺激，光伏板块今日表现强势，多只光伏概念股应声上扬。其中，**协鑫科技（03800）**涨幅居前，涨幅高达4.48%，展现出强劲的发展势头。

消息面上，本届SNEC展亮点频出，多项重磅技术和产品发布为光伏产业未来发展注入强劲动力。 其中，隆基绿能发布了全球首款突破90%效率的钙钛矿太阳能电池，协鑫科技则推出了新一代高性能光伏组件，引发业界广泛关注。

分析人士表示，光伏板块近期强势上涨主要有以下几个原因：

• 一是政策利好持续释放。 近年来，国家层面不断出台支持光伏产业发展的政策措施，为光伏产业发展提供了强劲的政策支撑。
• 二是光伏产业技术持续进步。 随着光伏电池技术不断进步、生产成本持续下降，光伏发电的经济性日益凸显，应用领域不断拓展。
• 三是全球能源格局深刻变革。 在俄乌冲突和全球能源价格飙升的背景下，各国加快推进能源转型，光伏作为清洁、可再生能源受到越来越广泛的重视。

业内人士普遍看好光伏产业未来发展前景。 预计未来随着光伏发电成本进一步下降、应用领域不断拓展，光伏产业将迎来更加广阔的发展空间。

具体来看，协鑫科技作为光伏产业链龙头企业，在技术创新、产品研发、市场拓展等方面拥有明显的竞争优势。 公司近年来业绩保持快速增长，未来有望继续受益于光伏产业的高景气度。

以下是一些与本次新闻相关的股票信息：

• 协鑫科技（03800）：公司主要从事光伏组件、光伏玻璃、光伏硅片等光伏产品的研发、生产和销售。
• 隆基绿能（600478）：公司主要从事单晶硅光伏组件的研发、生产和销售。
• 晶澳科技（002459）：公司主要从事光伏组件的研发、生产和销售。

免责声明： 本文仅供参考，不构成投资建议。投资者应根据自身情况谨慎投资。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.